We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
-3.23%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$4.84B
AUM Growth
-$282M
Cap. Flow
-$20.2M
Cap. Flow %
-0.42%
Top 10 Hldgs %
88.92%
Holding
82
New
22
Increased
15
Reduced
12
Closed
13

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$19.3M
2
TSLA icon
Tesla
TSLA
+$17M
3
USFD icon
US Foods
USFD
+$12.2M
4
FOLD
Amicus Therapeutics
FOLD
+$8.74M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$6.93M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$37.2M
2
MA icon
Mastercard
MA
+$18.9M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$14.2M
4
JPM icon
JPMorgan Chase
JPM
+$12.5M
5
DAL icon
Delta Air Lines
DAL
+$9.74M

Sector Composition

Rank Sector Weight
1 Consumer Staples 55.65%
2 Healthcare 23.71%
3 Miscellaneous 10.68%
4 Consumer Discretionary 8.41%
5 Financials 1.55%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JPM icon
76
JPMorgan Chase
JPM
$916B
– –
-200,000
Closed -$12.5M
HAPN
77
Happen Inc
HAPN
$1.9B
– –
-225,000
Closed -$9.34M
MA icon
78
Mastercard
MA
$501B
– –
-200,000
Closed -$18.9M
PANW icon
79
Palo Alto Networks
PANW
$310B
– –
-120,000
Closed -$3.26M
TEVA icon
80
CALL
Teva Pharmaceuticals
TEVA
$45.8B
– –
-450,000
Closed -$24.1M
CELG
81
DELISTED
Celgene Corp
CELG
– –
-360,000
Closed -$37.2M
PARN
82
DELISTED
Parnell Pharmaceuticals Holdings Ltd
PARN
– –
-500,000
Closed -$1.06M
1 2 3
4

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q2 2016 Portfolio in Review

As of Q2 2016, Artal Group held 82 positions worth $4.84B, down 5.5% from $5.13B the previous quarter. Its ten largest holdings account for 89% of the portfolio.

Artal Group's Q2 2016 filing shows 22 new, 15 increased, 12 reduced and 13 closed positions. Its largest new stake was Regeneron Pharmaceuticals: 50,000 shares worth $17.5M. The largest sale was Celgene Corp, an estimated $37.2M.

By sector, the portfolio is most concentrated in Consumer Staples at 56% of assets, down from 58% a quarter earlier, followed by Healthcare and Miscellaneous.

  • Artal Group's largest Q2 2016 buy was Regeneron Pharmaceuticals: 50,000 shares worth $17.5M.
  • Artal Group added most to Alnylam Pharmaceuticals in Q2 2016, an estimated $6.93M increase.
  • Artal Group's biggest Q2 2016 reduction was Nektar Therapeutics, cutting an estimated $8.94M.
  • Artal Group fully exited Celgene Corp in Q2 2016, selling an estimated $37.2M.
  • Artal Group's ten largest holdings make up 89% of its $4.84B portfolio in Q2 2016.
  • Artal Group opened 22 new positions and closed 13 in Q2 2016.
  • Artal Group's portfolio value fell 5.5% quarter-over-quarter to $4.84B.

Based on Artal Group's 13F filing for Q2 2016, filed 11 Aug 2016.